News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Merck & Co., Inc.'s Stromectol Wipes Out Hard-to-Treat Lice, Study Finds
March 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Merck & Co.’s Stromectol tablet worked better than lotion at clearing up hard-to-treat head lice, a study found, as the infestations become increasingly resistant to current medicines.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Merck & Co.
MORE ON THIS TOPIC
Earnings
As Biogen Nears Presymptomatic Alzheimer’s Readout for Leqembi, Can Doctors Be Convinced?
October 30, 2025
·
2 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH ELEMENT
Innovation, Resilience, and the Future of Global Manufacturing
October 30, 2025
·
1 min read
·
BioSpace Insights
CAR-T
Kyverna’s CAR T Therapy Sets ‘New Efficacy Standard’ in Myasthenia Gravis, De-Risking Phase III Trials
October 30, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Novartis Presents New Data From Potential First Targeted Sjögren’s Treatment
October 29, 2025
·
3 min read
·
Heather McKenzie